• English (Australia)
    • German (Austria)
    • Dutch (Belgium)
    • English (Belgium)
    • French (Belgium)
    • German (Belgium)
    • Danish (Denmark)
    • French (France)
    • German (Germany)
    • Greek (Greece)
    • Italian (Italy)
    • Dutch (Netherlands)
    • Polish (Poland)
    • Swedish (Sweden)
    • French (Switzerland)
    • German (Switzerland)
    • Italian (Switzerland)

You are leaving this website

You are leaving this website and entering another website. Amgen is not responsible for the content or adopting such content into this website.

Go back Continue
Website Logo Website Logo
  • About the Study
  • FAQs
  • Patient Resources
  • Site Resources
  • See if you qualify
Prostate Cancer Patient Prostate Cancer Patient

The XALute Study

A Clinical Study for Men With Advanced Prostate Cancer

Learn more
Prostate Cancer OncologistProstate Cancer Oncologist

What is the XALute Study?

The study is testing a new investigational immunotherapy called Xaluritamig for metastatic castration-resistant prostate cancer.

Prostate Cancer Oncologists reviewing test resultsProstate Cancer Oncologists reviewing test results

What happens during the study?

Participants will be in the study for about 5 years.

Prostate Cancer Patient and CaregiverProstate Cancer Patient and Caregiver

Interested in learning more?

Check out our list of frequently asked questions (FAQs).

Frequently asked questions

You are leaving this website

You are leaving this website and entering another website. Amgen is not responsible for the content or adopting such content into this website.

Go back Continue
Back to Top
Contact Us Terms of Use Privacy Statement Cookie Settings

© 2025 Amgen Inc. All rights reserved. | This site is intended for Australia residents only.